AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30672235 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment of superficial needling technique and mild moxibustion
Number of subjects: 60
Study 30672235 — intervention group
Group type: COMPARATOR
Intervention: Warm acupuncture
Number of subjects: 60
Study 28760148 — intervention group
Group type: COMPARATOR
Intervention: Exercise program for older married couples (CG)
Number of subjects: 93
Study 28760148 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-couple group (NCG)
Number of subjects: 93
Study 23778124 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic central lateral thalamotomy (CLT)
Number of subjects: 8
Study 23778124 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 8
Study 21558582 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-month intervention (INT)
Number of subjects: 41
Study 21558582 — intervention group
Group type: COMPARATOR
Intervention: usual care (UC)
Number of subjects: 41
Study 19705041 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-cleaning with a robot
Number of subjects: 12
Study 19705041 — intervention group
Group type: COMPARATOR
Intervention: Ordinary cleaning without the use of a robot
Number of subjects: 12
Study 16769912 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber ICDs
Number of subjects: 400
Study 16769912 — intervention group
Group type: COMPARATOR
Intervention: Single-chamber ICDs
Number of subjects: 400
Study 16769912 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 400
Study 15042531 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab in combination with fludarabine and cyclophosphamide
Number of subjects: 0
Study 15042531 — intervention group
Group type: COMPARATOR
Intervention: Rituximab monotherapy
Number of subjects: 0
Study 15042531 — intervention group
Group type: COMPARATOR
Intervention: Increased dosing intensity and frequency of rituximab
Number of subjects: 0
Study 11377899 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost 0.005% alone (Group 1)
Number of subjects: 0
Study 11377899 — intervention group
Group type: COMPARATOR
Intervention: Intracameral acetylcholine alone (Group 3)
Number of subjects: 0
Study 11377899 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% with intracameral acetylcholine (Group 2)
Number of subjects: 0
Study 11377899 — intervention group
Group type: COMPARATOR
Intervention: No medication (controls, Group 4)
Number of subjects: 0
Study 9442547 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulpiride (200 mg daily for 30 days)
Number of subjects: 0
Study 9442547 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7955519 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1LAI recombinant gp160 (rgp160) vaccine, 50-micrograms doses
Number of subjects: 30
Study 7955519 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 1 (0, 1, 2, and 5 months)
Number of subjects: 30
Study 7955519 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-1LAI recombinant gp160 (rgp160) vaccine, Group 2 (0, 1, 2, 3, and 4 months)
Number of subjects: 30
Study 3043359 — intervention group
Group type: EXPERIMENTAL
Intervention: ticarpen tobramycin
Number of subjects: 87
Study 3043359 — intervention group
Group type: COMPARATOR
Intervention: ticarpen moxalactam
Number of subjects: 87
Study 31736069 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbetocin (100 μg/mL intravenously)
Number of subjects: 150
Study 31736069 — intervention group
Group type: COMPARATOR
Intervention: Misoprostol (800 μg rectally)
Number of subjects: 150
Study 31016527 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% normal saline (IS)
Number of subjects: 48
Study 31016527 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% hypertonic saline (HS)
Number of subjects: 48
Study 31016527 — intervention group
Group type: EXPERIMENTAL
Intervention: double-distilled water (SW)
Number of subjects: 48
Study 31016527 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 48
Study 28320406 — intervention group
Group type: EXPERIMENTAL
Intervention: Three-session manualised psychosocial group intervention and BBV transmission information booklet plus treatment as usual (TAU)
Number of subjects: 99
Study 28320406 — intervention group
Group type: COMPARATOR
Intervention: Information booklet plus treatment as usual (TAU)
Number of subjects: 99
Study 25569072 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogenic (porcine) acellular dermal matrix (XADM)
Number of subjects: 36
Study 25569072 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen peroxide and sodium hypochlorite solution (control)
Number of subjects: 36
Study 23261792 — intervention group
Group type: COMPARATOR
Intervention: Watching videos
Number of subjects: 30
Study 23261792 — intervention group
Group type: COMPARATOR
Intervention: Social contingent reinforcement and vocal modeling with an adult
Number of subjects: 30
Study 23261792 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing alone with small toys
Number of subjects: 30
Study 23261792 — intervention group
Group type: EXPERIMENTAL
Intervention: Playing alone with large toys
Number of subjects: 30
Study 22022214 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflapin(®) 100 mg daily for 30 days
Number of subjects: 60
Study 22022214 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 18438112 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y reconstruction with pouch
Number of subjects: 138
Study 18438112 — intervention group
Group type: COMPARATOR
Intervention: Roux-en-Y reconstruction without pouch
Number of subjects: 138
Study 21901256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum with fructo-oligosaccharides (Fos) and lifestyle modification
Number of subjects: 66
Study 21901256 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle modification alone
Number of subjects: 66
Study 15988404 — intervention group
Group type: EXPERIMENTAL
Intervention: Antithyroid drugs (methimazole 5-20 mg/die/os) and diphosphonates (alendronate 10 mg/die/os)
Number of subjects: 26
Study 15988404 — intervention group
Group type: COMPARATOR
Intervention: Antithyroid drugs only
Number of subjects: 26
Study 12629097 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I (30 micro g/kg sc twice daily)
Number of subjects: 65
Study 12629097 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 12629097 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol) with rhIGF‐I
Number of subjects: 65
Study 12629097 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF‐I
Number of subjects: 65
Study 9619927 — intervention group
Group type: EXPERIMENTAL
Intervention: Double latex gloving without a disposable protective glove liner (Group 1)
Number of subjects: 118
Study 9619927 — intervention group
Group type: COMPARATOR
Intervention: Double latex gloving with a disposable protective glove liner (Group 2)
Number of subjects: 118
Study 7698300 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-3 (10 micrograms/kg)
Number of subjects: 32
Study 7698300 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIL-3
Number of subjects: 32
Study 7698300 — intervention group
Group type: COMPARATOR
Intervention: Control cycles (CHOP chemotherapy)
Number of subjects: 32
Study 2642668 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine-proglumide mixtures (proglumide doses per demand: 0, 50 micrograms, 100 micrograms, or 50 mg)
Number of subjects: 80
Study 2642668 — intervention group
Group type: COMPARATOR
Intervention: Morphine (demand dose 3 mg; infusion rate 0.36 mg/hr; lockout time 2 minutes; hourly maximum dose 15 mg/hr)
Number of subjects: 80
Study 981326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate
Number of subjects: 0
Study 981326 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31924543 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injection (IAI) 2 mg every 4 weeks, IAI 2 mg every 8 weeks after 5 monthly doses
Number of subjects: 54
Study 31924543 — intervention group
Group type: COMPARATOR
Intervention: Laser control
Number of subjects: 54
Study 29888580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee-venom acupuncture (5 to 15 bee stings at Ashi-points or acupoints, retained for about 5 min, once every other day for 8 weeks)
Number of subjects: 120
Study 29888580 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate (10 mg, once a week) and Celecoxib (0.2 g, once a day)
Number of subjects: 120
Study 29888580 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bee-venom acupuncture and control)
Number of subjects: 120
Study 29888580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bee-venom acupuncture
Number of subjects: 120
Study 25772957 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:200,000 adrenaline (Group A)
Number of subjects: 194
Study 25772957 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine/HCl with 1:100,000 adrenaline (Group B)
Number of subjects: 194
Study 23522723 — intervention group
Group type: EXPERIMENTAL
Intervention: Step‐N‐Tune activity monitor
Number of subjects: 12
Study 23522723 — intervention group
Group type: EXPERIMENTAL
Intervention: Activ4Life Pro V3.8 activity monitor
Number of subjects: 12
Study 23522723 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Device for Energy Expenditure and Activity
Number of subjects: 12
Study 23522723 — intervention group
Group type: COMPARATOR
Intervention: Healthy control group (n=12)
Number of subjects: 12
Study 21567259 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss intervention
Number of subjects: 338
Study 21567259 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 338
Study 18840204 — intervention group
Group type: EXPERIMENTAL
Intervention: 24% oral sucrose solution
Number of subjects: 40
Study 18840204 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 40
Study 16861101 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone (flexible dosing starting at 0.02 mg/kg/day, titrated up to 0.06 mg/kg/day)
Number of subjects: 110
Study 16861101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 12974590 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevidipine
Number of subjects: 30
Study 12974590 — intervention group
Group type: COMPARATOR
Intervention: Sodium Nitroprusside
Number of subjects: 30
Study 10755740 — intervention group
Group type: COMPARATOR
Intervention: Morphine 0 mg/70 kg
Number of subjects: 5
Study 10755740 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 4 mg/70 kg
Number of subjects: 5
Study 10755740 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 8 mg/70 kg
Number of subjects: 5
Study 10755740 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 16 mg/70 kg
Number of subjects: 5
Study 10755740 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 32 mg/70 kg
Number of subjects: 5
Study 10755740 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine (lowest and highest doses repeated)
Number of subjects: 5
Study 8677754 — intervention group
Group type: COMPARATOR
Intervention: High dose LPS (1 microgram/ml)
Number of subjects: 35
Study 8677754 — intervention group
Group type: COMPARATOR
Intervention: Lower LPS concentration (1 ng/ml)
Number of subjects: 35
Study 8677754 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF-alpha and IL-6 mRNA levels
Number of subjects: 35
Study 8677754 — intervention group
Group type: EXPERIMENTAL
Intervention: TNF and IL-6 mRNA half-life
Number of subjects: 35
Study 1577028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase
Number of subjects: 85
Study 1577028 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 1577028 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 85
Study 6694236 — intervention group
Group type: EXPERIMENTAL
Intervention: Early tracheostomy (34 patients)
Number of subjects: 74
Study 6694236 — intervention group
Group type: COMPARATOR
Intervention: Late tracheostomy (40 patients)
Number of subjects: 74
Study 6694236 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (74 patients)
Number of subjects: 74
Study 6694236 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid-posture, head-injured patients
Number of subjects: 74
Study 29336645 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised individually tailored exercise program (4-6 weeks), aerobic endurance, muscle strength, and relaxation exercises, administered twice a week
Number of subjects: 46
Study 29336645 — intervention group
Group type: COMPARATOR
Intervention: No exercise (control group)
Number of subjects: 46
Study 26607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Screen time (each additional hour)
Number of subjects: 497
Study 26607843 — intervention group
Group type: EXPERIMENTAL
Intervention: Outdoor playtime
Number of subjects: 497
Study 26374480 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year multicomponent intervention including self-help materials, tailored newsletters, and motivational interviewing counseling calls
Number of subjects: 801
Study 23211420 — intervention group
Group type: EXPERIMENTAL
Intervention: LCPUFA (n-3 long-chain polyunsaturated fatty acids) supplementation at 84 g/day from day 60 of gestation through 21-day lactation and until day 30 of second gestation
Number of subjects: 117
Study 23211420 — intervention group
Group type: COMPARATOR
Intervention: Control sows (CON) fed standard gestation and lactation diets
Number of subjects: 117
Study 21769058 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (21 mg transdermal patch)
Number of subjects: 8
Study 21769058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (transdermal patch)
Number of subjects: 8
Study 18392378 — intervention group
Group type: EXPERIMENTAL
Intervention: Temporary biatrial pacing
Number of subjects: 98
Study 18392378 — intervention group
Group type: COMPARATOR
Intervention: No biatrial pacing (control)
Number of subjects: 98
Study 17201614 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 87
Study 17201614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 87
Study 16429181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with LA Axxess burs
Number of subjects: 50
Study 16429181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with ProTaper instruments
Number of subjects: 50
Study 16429181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with Gates‐Glidden drills
Number of subjects: 50
Study 16429181 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical preflaring with K3 Orifice Opener instruments
Number of subjects: 50
Study 16429181 — intervention group
Group type: COMPARATOR
Intervention: No cervical preflaring (Control)
Number of subjects: 50
Study 11137838 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Umbrella (DU)
Number of subjects: 38
Study 11137838 — intervention group
Group type: COMPARATOR
Intervention: Wire Coil (WC)
Number of subjects: 38
Study 9042638 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2c plus standard induction chemotherapy (three cycles of cyclophosphamide/vincristine/doxorubicin and cisplatin/etoposide plus subcutaneous IFN-alpha-2c)
Number of subjects: 85
Study 9042638 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 85
Study 8198267 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Number of subjects: 12
Study 8198267 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous alfentanil (1 mg along with 0.2 mg/h and 0.2-mg boluses on demand)
Number of subjects: 12
Study 3440099 — intervention group
Group type: EXPERIMENTAL
Intervention: N-desmethylclobazam (NDMC) 30 mg single dose
Number of subjects: 16
Study 3440099 — intervention group
Group type: COMPARATOR
Intervention: Clobazam 30 mg single dose
Number of subjects: 16
Study 29873093 — intervention group
Group type: EXPERIMENTAL
Intervention: Indoor play space
Number of subjects: 496
Study 29873093 — intervention group
Group type: COMPARATOR
Intervention: Portable play equipment
Number of subjects: 496
Study 29873093 — intervention group
Group type: COMPARATOR
Intervention: Outdoor physical environment
Number of subjects: 496
Study 27554227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexem group (15 mL of 0.75% ropivacaine plus dexmedetomidine, 1 µg/kg bolus, followed by 0.2 µg/kg/hour infusion)
Number of subjects: 30
Study 27554227 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexem group
Number of subjects: 30
Study 27554227 — intervention group
Group type: COMPARATOR
Intervention: Ropin group
Number of subjects: 30
Study 26335989 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study 26335989 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23537008 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Intensity Focused Ultrasound (HIFU)
Number of subjects: 0
Study 23537008 — intervention group
Group type: COMPARATOR
Intervention: Conventional Myomectomy (MY)
Number of subjects: 0
Study 21288094 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent HPV vaccine
Number of subjects: 4065
Study 18496358 — intervention group
Group type: EXPERIMENTAL
Intervention: Management with a PAC
Number of subjects: 0
Study 18496358 — intervention group
Group type: COMPARATOR
Intervention: Alternative flow measurement device
Number of subjects: 0
Study 16540957 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam plus fentanyl (co-sedation)
Number of subjects: 30
Study 16540957 — intervention group
Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 30
Study 14515937 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Ashworth Scale of Spasticity (MAS)
Number of subjects: 18
Study 14515937 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive Range of Movement (PROM)
Number of subjects: 18
Study 14515937 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Tardieu Scale (MTS)
Number of subjects: 18
Study 10341684 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment of resected specimens
Number of subjects: 26
Study 10341684 — intervention group
Group type: COMPARATOR
Intervention: Histopathological examination
Number of subjects: 26
Study 10341684 — intervention group
Group type: EXPERIMENTAL
Intervention: MR imaging of resected specimens
Number of subjects: 26
Study 10341684 — intervention group
Group type: EXPERIMENTAL
Intervention: MR examinations
Number of subjects: 26
Study 10341684 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI assessment
Number of subjects: 26
Study 7498356 — intervention group
Group type: EXPERIMENTAL
Intervention: Informed consent
Number of subjects: 3217
Study 7498356 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised consent (for experimental therapy)
Number of subjects: 3217
Study 7498356 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised consent (for standard therapy)
Number of subjects: 3217
Study 2031498 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment in TOHP (Trials of Hypertension Prevention)
Number of subjects: 0
Study 2031498 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment in HPT (Hypertension Prevention Trial)
Number of subjects: 0
Study 2031498 — intervention group
Group type: COMPARATOR
Intervention: Control group (black control subjects)
Number of subjects: 0
Study 7214987 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam intravenous supplement
Number of subjects: 113
Study 7214987 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo (solvent of diazepam only)
Number of subjects: 113
Study 29232526 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental support program based on motivational interviewing (MI) delivered by nurses in Swedish child health services, with nine sessions over ∼39 months.
Number of subjects: 1355
Study 29232526 — intervention group
Group type: COMPARATOR
Intervention: Control group received usual healthcare.
Number of subjects: 1355
Study 25794890 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed surgical oophorectomy during the midluteal phase of the menstrual cycle
Number of subjects: 740
Study 25794890 — intervention group
Group type: COMPARATOR
Intervention: Immediate surgical oophorectomy
Number of subjects: 740
Study 23018784 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronate (ZOL)
Number of subjects: 107
Study 23018784 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLB)
Number of subjects: 107
Study 21109054 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical spine joint mobilization
Number of subjects: 23
Study 21109054 — intervention group
Group type: COMPARATOR
Intervention: Sedative massage
Number of subjects: 23
Study 18992135 — intervention group
Group type: EXPERIMENTAL
Intervention: COACH prompting system
Number of subjects: 6
Study 16816950 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg twice daily)
Number of subjects: 31
Study 16816950 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 12686397 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory tasks of mental calculation
Number of subjects: 24
Study 12686397 — intervention group
Group type: EXPERIMENTAL
Intervention: Trail Making Test (TMT)
Number of subjects: 24
Study 12686397 — intervention group
Group type: EXPERIMENTAL
Intervention: Kana Pick-out Test
Number of subjects: 24
Study 12686397 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 24
Study 10666970 — intervention group
Group type: EXPERIMENTAL
Intervention: Galloy restorations sealed with PAAMA 2 dentine adhesive system
Number of subjects: 37
Study 10666970 — intervention group
Group type: COMPARATOR
Intervention: Tytin restorations without adhesive sealer
Number of subjects: 37
Study 8689371 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive outreach case management for periods ranging from 15 to 52 months after discharge
Number of subjects: 292
Study 8689371 — intervention group
Group type: COMPARATOR
Intervention: Standard aftercare services
Number of subjects: 292
Study 1715503 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital rectal screening and prostate-specific antigen (PSA) measurement
Number of subjects: 814
Study 1715503 — intervention group
Group type: EXPERIMENTAL
Intervention: Transrectal ultrasonography
Number of subjects: 814
Study 1715503 — intervention group
Group type: EXPERIMENTAL
Intervention: Biopsy
Number of subjects: 814